生物帮生物通

采购帮忙热线
020-87540820
020-38498013
 
当前位置: 首页 » 行业资讯 » 行业资讯 » 正文

强生与Genmab新增19亿美元合作获额外10个抗体项目

放大字体  缩小字体 发布日期:2013-12-06  浏览次数:6

强生(JNJ)旗下杨森(Janssen)与丹麦生物制药公司Genmab 12月4日联合宣布,已扩大了双方的合作,将利用DuoBody技术平台创造和开发双特异性抗体(bispecific antibodies)。最初达成的协议,赋予杨森开发多达10个DuoBody项目的权利。根据修正后的协议条款,杨森将获得开发额外10个项目的权利。

Genmab将获得一笔200万美元的预付款。对于新增的10个额外项目,在杨森成功启动、开发、商业化后,Genmab将有资格从每个项目中获得1.74亿-2.19亿美元的里程碑款项及授权款项,这取决于何时每个项目的启动时间。在最有利的情况下,即10个额外项目均成功实现启动、开发、商业化后,Genmab将从每个项目中平均获得1.91亿美元的里程碑款和授权款,总额高达19.1亿美元。此外,Genmab还将有权获得产品商业化销售的特许权使用费。

强生与Genmab于2012年7月签署了高达11亿美元的初步合作协议,包括一笔5500万美元的预付款,收购Genmab价值8000万美元的股权获得10.75的股份,及相关的里程碑款项。该项合作,强生获得了一种潜力巨大的抗体daratumumab,这是一种针对多发性骨髓瘤的CD38抗体,杨森拥有这一抗体的全球权利。daratumumab针对CD38进行多发性骨髓瘤治疗,在临床前试验阶段产生了极好的数据。

关于DuoBody平台:

DuoBody平台是一种创新的抗体平台,发现和开发可能改善癌症、自身免疫、感染、中枢神经系统疾病临床治疗的双特异性抗体(bispecfic antibodies)。

双特异性抗体靶向结合至相同或不同靶标(也称为双靶向,dual-targeting)上的2个不同表位(epitope),可改善抗体失活(inactive)疾病靶标的特异性和效力。DuoBody分子是一种独特的分子,将双特异性的益处与常规抗体的优势相结合,使DuoBody能够以其他抗体药物的方式和剂量给药。Genmab公司的DuoBody平台通过一种快速且广泛适用的过程产生双特异性抗体,很容易扩大至商业化生产规模。

在与强生合作之前,Genmab已与葛兰素史克(GSK)、罗氏(Roche)建立了合作伙伴关系。

 

Genmab Announces Expansion of DuoBody Platform Collaboration with Janssen Biotech, Inc.

PDF PDF

 

 

Company Announcement

  • DuoBody® platform collaboration with Janssen expanded to include additional programs
  • Genmab receives initial payment of $2 million

Copenhagen, Denmark; December 4, 2013 — Genmab A/S (OMX: GEN) announced today an expansion of its collaboration with Janssen Biotech, Inc. ("Janssen") to create and develop bispecific antibodies using the DuoBody technology platform.  The original agreement entitled Janssen to work on up to ten DuoBody programs. Under the terms of the amendment, Janssen is entitled to work on up to ten additional programs.

Genmab will receive an initial payment of $2 million (approximately DKK 11 million) from Janssen.  For each of the ten additional programs that Janssen successfully initiates, develops and commercializes, Genmab will potentially be entitled to milestone and license payments of up to approximately $174 million (DKK 956 million) to $219 million (DKK 1.2 billion), depending on the date each program is initiated.  In the most favorable scenario in which all ten additional programs are successfully initiated, developed and commercialized, Genmab would receive average milestone and license payments of approximately $191 million (DKK 1.0 billion) for each of the ten programs. In addition, Genmab will be entitled to royalties on sales of any commercialized products. 

"Our DuoBody collaboration with Janssen has been very productive since we signed the initial agreement in July 2012.  We are excited about the potential to work with Janssen on additional programs," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. 

This agreement does not materially impact Genmab's 2013 financial guidance.

About the DuoBody Platform

The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies' specificity and efficacy in inactivating the disease targets. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development.  Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates.  Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit
www.genmab.com.

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

 
 
[ 行业资讯搜索 ]  [ 加入收藏 ]  [ 告诉好友 ]  [ 打印本文 ]  [ 关闭窗口 ]

0条 [查看全部]  相关评论

 
推荐行业资讯
点击排行
 
网站首页 | 企业资料认证流程 | 广告服务 | 关于我们 | 联系方式 | 使用协议 | 网站地图 | 排名推广 | 广告服务 | 网站留言 | RSS订阅 | 粤ICP备11050685号-8